Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?
Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price. Before you chase the rally, there are some uncomfortable numbers you need to see first.
Moderna (NASDAQ:MRNA | MRNA Price Prediction) has risen 658.2% year to date, from $29.49 at the end of 2025 to $223.60 in premarket trading on Thursday. That premarket price is 1.2% below Wednesday’s $226.30 close. Investors who missed the run now face a valuation question. Analyst targets and valuation data help answer that question.
Melanoma Data Turned a COVID Stock Into a Cancer Story
On August 19, shares rose 177%, Moderna’s best day ever. The jump came after its personalized cancer vaccine, developed with Merck (NYSE:MRK), showed promise in its first late-stage trial. Before that, five-year Phase 2b data presented at ASCO 2026 showed a 49% reduction in the risk of return or death when intismeran was added to Keytruda. Jim Cramer called the vaccine “miraculous” on Mad Money on August 31. On October 1, he said the shift away from COVID “verifies the excitement and the move.” Valuation metrics add harder numbers to that view.
Moderna has four approved products: Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX. It also has nine Phase 2/3 intismeran trials covering melanoma, lung, bladder and kidney cancer, plus rare disease programs. On September 25, a panelist on CNBC’s Fast Money said investors now see that “Moderna could have six or seven drugs by 2028.”
Analysts Value Moderna Far Below Its Price
The consensus analyst price target is $122.67, well below the current share price. A separate valuation model puts fair value at $134.45 and rates the stock at Sell. Hold ratings dominate the analysts’ consensus. Shares trade at 38.75 times trailing sales. When a stock trades this far above analyst targets, either Wall Street has not caught up with the story or the stock has gotten ahead of the company’s results. Investors have to decide which.
The Five-Year Chart Most Coverage Skips
Even after this run, shares are 31.0% below their price five years ago, when they traded at $324.21. The valuation model still flags a sharp year-over-year earnings decline. Moderna lost $782 million in the second quarter on revenue of $145 million. The pipeline also carries risk: the norovirus vaccine failed to meet its statistical endpoints at a Phase 3 interim analysis. Today, the share price reflects future pipeline value amid ongoing losses.
November 6 Is the Next Test
Third-quarter results are scheduled for November 6, and management expects about 55% of second-half revenue to land in the third quarter. Investors will see whether that happens. The report also needs to show cash on track for $4.7 billion to $5.2 billion at year end, along with a regulatory timeline for intismeran. In July, management said that if the melanoma data were positive, “we would obviously make the case for an accelerated review.”
Concentration Risk Looms Over Biotech Rallies
On August 27, Suze Orman spoke with a caller whose partner had pushed her to put everything into a single biotechnology stock. Orman called that “reckless speculation.” Orman also asked why he hadn’t made the investment himself: “Why didn’t he, if he was so certain, build his own savings and invest his own money?” She was warning about concentration and process, and that point applies at any price. A little speculative exposure to a story like Moderna’s can work if it stays small and follows rules, the sizing and safety rails we laid out in a free speculation guide. Concentration in one clinical-stage biotech magnifies portfolio risk.
Verdict: Price Runs Far Ahead of Valuations
At this price, Moderna trades well ahead of both analyst and model valuations. The $223.60 share price is far above both the $122.67 analyst consensus and the $134.45 model estimate. That means the price already assumes regulatory approval, a successful launch, and strong sales that Moderna has not delivered yet. If the cancer vaccine succeeds, the upside case improves. If anything slips, the gap between the current price and analyst targets leaves room for a painful drop. The November 6 report and further regulatory progress will show whether results can catch up to the share price.
Contact [email protected] for any questions or corrections.
Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.
Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community.
Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.
Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, moderating workshop sessions at regional conventions.
